Effectiveness Of Intravitreal Bevacizumab In The Treatment Of Neovascular Age-Related Macular Degeneration: Visual And Anatomical Results - A Real-Life Retrospective Study.

Objective: To evaluate the effectiveness intravitreal bevacizumab in the treatment of neovascular macular degeneration (n-ARMD) in a real-life scenario. Method: Retrospective, longitudinal study that evaluated the medical records of 101 eyes (89 patients) with n-ARMD who received intravitreal bevacizumab, in a Pro Re Nata (PRN) treatment regimen, between July 2021 and March 2024. Results: After one year of follow-up, 41 eyes (41.4%) showed improvement in VA, 32 (32.3%) showed a decline in VA, and 26 (26.3%) maintained stable VA. There was a significant reduction in median central macular thickness, with a decrease from 317 µm at baseline to 271 µm (p-value < 0.001; ∆ = 46 µm). Of all variables evaluated, the number of visits was the only modulator significantly correlated with VA improvement (p = 0.008). Conclusion: In our study, the majority of patients treated with Bevacizumab improved or maintained their CCVA status. Therefore, bevacizumab in a PRN regimen was effective in the treatment of n-ARMD, supporting its use in a high-throughput public service. Our study also reinforced the clinical application of OCT-based anatomical results to individualize and optimize therapeutic strategies and protocols for patients Financial Disclosure(s): The author(s) have no commercial interest in any of the discussed subjects.